2018
The influence of mutational status and biological characteristics of acute myeloid leukemia on xenotransplantation outcomes in NOD SCID gamma mice
ČULEN, Martin, Zdeňka KOSAŘOVÁ, Ivana JEŽÍŠKOVÁ, A. FOLTA, Jana CHOVANCOVÁ et. al.Základní údaje
Originální název
The influence of mutational status and biological characteristics of acute myeloid leukemia on xenotransplantation outcomes in NOD SCID gamma mice
Autoři
ČULEN, Martin (703 Slovensko, domácí), Zdeňka KOSAŘOVÁ (203 Česká republika, domácí), Ivana JEŽÍŠKOVÁ (203 Česká republika), A. FOLTA (203 Česká republika), Jana CHOVANCOVÁ (203 Česká republika, domácí), Tomáš LOJA (703 Slovensko, domácí), Nikola TOM (203 Česká republika, domácí), Vojtěch BYSTRÝ (203 Česká republika, domácí), V. JANECKOVA (203 Česká republika), Dana DVOŘÁKOVÁ (203 Česká republika, domácí), Jiří MAYER (203 Česká republika, domácí) a Zdeněk RÁČIL (203 Česká republika, garant, domácí)
Vydání
Journal of cancer research and clinical oncology, New York, Springer-Verlag, 2018, 0171-5216
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30204 Oncology
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Impakt faktor
Impact factor: 3.332
Kód RIV
RIV/00216224:14110/18:00103216
Organizační jednotka
Lékařská fakulta
UT WoS
000435380600004
Klíčová slova anglicky
AML; Engraftment; NOD SCID gamma; Mutations; Sequencing
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 2. 5. 2019 13:30, Soňa Böhmová
Anotace
V originále
This study aimed at analyzing the association of gene mutations and other acute myeloid leukemia (AML) characteristics with engraftment outcomes in immunodeficient mice and to select the engraftment outcomes that best reflect patient survival. Mutations in 19 genes as well as leukemia- and patient-related characteristics were analyzed for a group of 47 de novo AML samples with respect to three engraftment outcomes: engraftment ability, engraftment intensity (percentage of hCD45(+) cells) and engraftment latency. Leukemia-related characteristics were additionally analyzed in an extended group of 68 samples that included the 47 de novo samples, and additional 21 samples from refractory and relapsed cases. Engraftment outcomes were compared with overall and event-free survival of the patients. For the 47 de novo samples, no single mutation influenced engraftment, whereas the NPM1 (mut) /DNMT3A (mut) co-mutation was associated with higher engraftment ability. NPM1 (mut) /FLT3-ITD (neg) had lower engraftment intensity. Among leukemia-related characteristics, a complex karyotype was associated with higher engraftment intensity. Among patient-related characteristics, higher cytogenetic risk was associated with higher engraftment intensity, and failure to achieve clinical remission was associated with shorter engraftment latency. In the extended group of 68 samples, white blood count was associated with higher engraftment ability, and the presence of a complex karyotype was associated with higher engraftment intensity. Association with patient overall survival was seen only for engraftment intensity. The engraftment of AML was influenced by mutation-interactions and other AML characteristics, rather than by single mutated genes, and engraftment intensity best reflected clinical penetrance of AML.
Návaznosti
MUNI/A/0968/2017, interní kód MU |
| ||
NV15-25809A, projekt VaV |
|